Non-canonical mechanisms of excitotoxicity
Non-canonical mechanisms of excitotoxicity
批准号:
10679904
负责人:
Michael Bennett
金额:
$3.96万
依托单位国家:
美国
项目类别:
财政年份:
2023
资助国家:
美国
项目状态:
未结题
起止时间:
2023-05-01 至 2025-04-30
关键词:
Acute Brain InjuriesAddressAnimal ModelAreaBlood VesselsBrainBrain InjuriesCationsCellsCerebrovascular CirculationCessation of lifeClinicalClinical TrialsComplexDistalElectrophysiology (science)EventFailureFutureGlutamatesGoalsHomeostasisHourImaging TechniquesInfarctionInjuryInterventionIntervention StudiesIschemiaIschemic StrokeKnock-outLinkLiteratureMeasuresMediatingMetabolicMethodsModelingMusN-MethylaspartateNeuronal InjuryNeuronsOutcomePathway interactionsPatientsPreventionProteinsRecoveryResearchRoleSliceSourceStrokeSystemTestingTherapeutic InterventionTissuesToxic effectTranslatingWorkbrain tissuecell injurychelationclinically relevantexcitotoxicityexperimental studyextracellularfluorescence imaginghypoperfusionimaging approachimprovedin vivoin vivo Modelknock-downneuroprotectionneurotoxicnovelnovel strategiespharmacologicpostsynapticpre-clinicalpresynapticpreventreceptorstroke modeltherapeutic targetuptakevoltage
中文摘要
点击翻译按钮获取中文摘要
英文摘要
PROJECT SUMMARY
This project addresses the underlying mechanisms that progress ischemic damage of vulnerable tissue that
surround acute brain injuries such as stroke. Our long-term goal is to identify the specific mechanisms that
transition metabolically compromised tissue to damaged, pro-death penumbra and to develop clinically relevant
therapeutic targets to improve patient survival after brain injury. While understanding of ischemic methods of
neuronal injury has been the primary focus, exploring specific mechanisms of consequence and potential
therapeutic targets has lagged far behind. This project looks specifically at Spreading Depolarizations (SDs)
which have recently been identified as contributing significantly to the progression of injury in vulnerable
penumbra. The main focus of these events has been on their contribution to prolonged NMDA-mediated Ca2+
influx and subsequent damage. However, SDs present a much more complex and underexplored surge of pre-
synaptic cation release and post-synaptic uptake through alternate pathways. Specifically both post-synaptic
activation of voltage-gated Ca2+ channels and increase in extracellular Zn2+ release and uptake have been linked
to the initiation and subsequent propagation of SD. Our central hypothesis is that SD-induced injury progression
in metabolically depleted tissue is mediated by dysregulation of non-NMDA-centric cation homeostasis.
Furthermore, agents that are selective to reduce alternative Ca2+ channel activation and/or decrease post-
synaptic Zn2+ uptake will reduce the downstream mediated damage that occurs following SD. We will use brain
slice and animal models to explore Zn2+ and Ca2+ specific mechanisms of injury as well as pharmacological
intervention to support compromised tissue during and after onset of SD. Specific Aim 1 focuses on the
hypothesis that neuronal voltage-gated Ca2+ channels contribute to post-synaptic uptake of intracellular Ca2+ and
lead to downstream cell execution. Neuronal Ca2+ loading will be assessed using a specific genetically modified
model and pharmacological intervention will be used to assess recovery in a metabolically compromised tissue
setting. Specific Aim 2 tests the hypothesis that disruption of Zn2+ homeostasis contributes to mechanisms of
SD-induced injury in vulnerable setting. Zn2+ wave in vulnerable tissue and specific stores of Zn2+ will be
assessed to explore where damaging levels are released. Specific Aim 3 then assess these mechanisms in an
in vivo setting. In all aims, both electrophysiological and imaging techniques will be used to assess specific
mechanisms in brain slice (Aim 1 and 2) and then translate into in vivo model (Aim 3). Pharmacological
intervention and specific knockdown models will explore where these cations contributions to damage and
identify where damaging levels of these cations originate. Completion of these aims should ascertain specific
mechanisms of Ca2+ and Zn2+-mediated injury following SD in vulnerable tissue and propose potential targets for
clinical prevention paradigms.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
BLOCKING NEGATIVE SIGNALS TO NK CELLS TO TREAT LEUKEMIA
-
批准号:6376235
-
项目类别:
-
资助金额:$21.06万
-
财政年份:2000
-
负责人:Michael Bennett
-
依托单位:
PATHOLOGY UTSWMC
-
批准号:6340695
-
项目类别:
-
资助金额:$12.43万
-
财政年份:2000
-
负责人:Michael Bennett
-
依托单位:
BLOCKING NEGATIVE SIGNALS TO NK CELLS TO TREAT LEUKEMIA
-
批准号:6633105
-
项目类别:
-
资助金额:$21.06万
-
财政年份:2000
-
负责人:Michael Bennett
-
依托单位:
BLOCKING NEGATIVE SIGNALS TO NK CELLS TO TREAT LEUKEMIA
-
批准号:6131639
-
项目类别:
-
资助金额:$21.06万
-
财政年份:2000
-
负责人:Michael Bennett
-
依托单位:
BLOCKING NEGATIVE SIGNALS TO NK CELLS TO TREAT LEUKEMIA
-
批准号:6512815
-
项目类别:
-
资助金额:$21.06万
-
财政年份:2000
-
负责人:Michael Bennett
-
依托单位:
INTERNATIONAL CONFERENCE ON THE CEROID-LIOPFUSCINOSES
-
批准号:2723292
-
项目类别:
-
资助金额:$2.15万
-
财政年份:1998
-
负责人:Michael Bennett
-
依托单位:
TOLERANCE TO BONE MARROW TRANSPLANTS
-
批准号:6100018
-
项目类别:
-
资助金额:$16.25万
-
财政年份:1998
-
负责人:Michael Bennett
-
依托单位:
TOLERANCE TO BONE MARROW TRANSPLANTS
-
批准号:6235437
-
项目类别:
-
资助金额:$15.62万
-
财政年份:1997
-
负责人:Michael Bennett
-
依托单位:
BLOCKING NEGATIVE SIGNALS TO NK CELLS TO TREAT LEUKEMIA
-
批准号:2114084
-
项目类别:
-
资助金额:$17.78万
-
财政年份:1996
-
负责人:Michael Bennett
-
依托单位:
BLOCKING NEGATIVE SIGNALS TO NK CELLS TO TREAT LEUKEMIA
-
批准号:2390914
-
项目类别:
-
资助金额:$18.3万
-
财政年份:1996
-
负责人:Michael Bennett
-
依托单位:
BLOCKING NEGATIVE SIGNALS TO NK CELLS TO TREAT LEUKEMIA
-
批准号:2683639
-
项目类别:
-
资助金额:$18.84万
-
财政年份:1996
-
负责人:Michael Bennett
-
依托单位:
BLOCKING NEGATIVE SIGNALS TO NK CELLS TO TREAT LEUKEMIA
-
批准号:2895496
-
项目类别:
-
资助金额:$19.37万
-
财政年份:1996
-
负责人:Michael Bennett
-
依托单位:
PATHOLOGY UTSWMC
-
批准号:6212451
-
项目类别:
-
资助金额:$12.43万
-
财政年份:1995
-
负责人:Michael Bennett
-
依托单位:
BATTEN DISEASE, MEMBRANE LIPIDS AND SIGNAL TRANSDUCTION
-
批准号:3417105
-
项目类别:
-
资助金额:$8.03万
-
财政年份:1992
-
负责人:Michael Bennett
-
依托单位:
BATTEN DISEASE, MEMBRANE LIPIDS AND SIGNAL TRANSDUCTION
-
批准号:2268225
-
项目类别:
-
资助金额:$8.92万
-
财政年份:1992
-
负责人:Michael Bennett
-
依托单位:
BATTEN DISEASE, MEMBRANE LIPIDS AND SIGNAL TRANSDUCTION
-
批准号:3417103
-
项目类别:
-
资助金额:$11.18万
-
财政年份:1992
-
负责人:Michael Bennett
-
依托单位:
IMMUNOGENETICS OF HYBRID RESISTANCE
-
批准号:2089197
-
项目类别:
-
资助金额:$25.77万
-
财政年份:1984
-
负责人:Michael Bennett
-
依托单位:
IMMUNOBIOLOGY OF HYBRID RESISTANCE
-
批准号:2089200
-
项目类别:
-
资助金额:$19.26万
-
财政年份:1984
-
负责人:Michael Bennett
-
依托单位:
IMMUNOGENETICS OF HYBRID RESISTANCE
-
批准号:3174577
-
项目类别:
-
资助金额:$8.79万
-
财政年份:1984
-
负责人:Michael Bennett
-
依托单位:
IMMUNOGENETICS OF HYBRID RESISTANCE
-
批准号:3174580
-
项目类别:
-
资助金额:$27.11万
-
财政年份:1984
-
负责人:Michael Bennett
-
依托单位:
海外基金